{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18","upperLimit":"45","value":"29"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Disease Progression: The day when bone marrow recurrence and/or new lytic bone marrow lesions on radiograph and/or progressive M-component paraprotein (\\~ 25% increase) were detected. Paraprotein progression will be confirmed labs on the consecutive month.","dispersionType":"Full Range","groups":[{"description":"autologous peripheral blood progenitor cell transplantation with bortezomib maintenance as treatment for intermediate-and advanced-stage multiple myeloma","id":"OG000","title":"Bortezomib"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"signed consent to progression or end of trial. Up to 5 years.","title":"Progression-free Survival","type":"PRIMARY","unitOfMeasure":"months"}